ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS ESCI Q2Scopus Q2SCImago #3,861Gold OA

Oncology and Therapy

Acronym:onth
•
Identifier (ISSN):2366-1070(Print)/2366-1089(Online)
•
Publisher:Adis, Springer Healthcare
Clarivate JCR Index Advisory: Active (ESCI)
Clarivate IF (2026)
3.4↑ +0.2
Journal Impact Factor
IF Trend↓
WoS Quartile
Q2
WoS ESCIJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2023–2026)

Clarivate IF trend for Oncology and Therapy

WoS Q2
12452.720233.220243.220253.42026
Annual Impact Factor Metric
Current (2026):3.4
Scopus SJR & RankScopus Q2
1.159
#3,861

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
24

24 papers with at least that number of citations each

WoS: ESCIQ2
Self-Citation Rate0%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessGold OA
42articles/year
100% Gold OA•64.52% Original Research

Aims & Scope

Now indexed in PubMed Aims and Scope Oncology and Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Oncology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital features and plain language summaries Oncology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor. Copyright Oncology and Therapy's content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0 Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of £3650/€4500/$5100. The journal will consider fee discounts for developing countries and this is decided on a case by case basis. Open Access All articles published by Oncology and Therapy are published open access Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at [email protected].

Topics Covered (Recognized by AI)
MedicineBiologyInternal MedicineGeneticsOncology & Cancer ResearchPathologyOncologySurgeryChemistryBiochemistryImmunologyCancer ResearchPsychologyPharmacologyRadiology
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRESCI2026

ONCOLOGY

Q2
Rank148/333
IndexESCI
JCIESCI2026

ONCOLOGY

Q3
Rank210/333
IndexESCI

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

11 year
2026Latest
IF3.4
Articles / Year46
Total Citations18
2025
IF3.2
Articles / Year88
Total Citations139
2024
IF3.2
Articles / Year64
Total Citations276
2023
IF2.7
Articles / Year38
Total Citations346
2022
IF—
Articles / Year36
Total Citations482

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #3,861Scopus Q2SCImago Profile
Scopus Coverage:2016-2026
Scopus Broad Areas:Medicine
Scopus Citation Rank (SJR)Q2
1.159

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
3.14

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,243 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations398
3-Year Documents126
Citable Documents98

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)1

Citations in government and international policy documents

Female Author Rate46.1%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

OncologyQ2
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Oncology and Therapy (acronym: onth, ISSN: 2366-1070) is a peer-reviewed international scholarly journal in the field of ONCOLOGY, published by Adis, Springer Healthcare in United Kingdom. The periodical holds a Journal Impact Factor (JIF) of 3.40, ranking in quartile Q2 of Web of Science (ESCI), a Scopus SJR indicator of 1.159 (Q2), an H-index of 24.

The journal enforces rigorous peer evaluation with a publication frequency of 2 issues per year, an annual output of approximately 42 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,243 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Gold OA
Publisher
Adis, Springer Healthcare
Publication Language
English
Frequency
2 issues per year
Indexing & Databases
ESCIDOAJPubMed

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 18a6a370-ba68-4c6e-90d1-6d3e23df9302
Database Updated: 2026-09-28